Health TrialsbyHealthPanel

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Participants needed: 155
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: TORL Biotherapeutics, LLCUpdated: Sep 28, 2026Locations: 9
Eligibility criteria

Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A;... [+4]

T-cell lymphoma [+6]

Read more
Status: Recruiting

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer

Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: TORL Biotherapeutics, LLCUpdated: Jul 13, 2026Locations: 7
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 [+4]

Clear cell, mucinous, sarcomatous, mixed histology, low-grade/borderline, or non... [+8]

Read more
Status: Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

Participants needed: 90
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: TORL Biotherapeutics, LLCUpdated: Feb 13, 2026Locations: 14
Eligibility criteria

Advanced solid tumor [+3]

Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade ≤1] from... [+7]

Read more
Status: Recruiting

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Participants needed: 230
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: TORL Biotherapeutics, LLCUpdated: Dec 23, 2025Locations: 66
Eligibility criteria

Females ≥18 years of age (or the legal age of consent in the jurisdiction in whi... [+26]

Has not recovered [recovery is defined as National Cancer Institute Common Termi... [+22]

Read more